Table 2.
Characteristics | N (%) | AFU levels (U/L, mean ± SD) | p-Value |
---|---|---|---|
Patientsa | 196 (100%) | 16.35 ± 5.20 | |
Age | 0.144* | ||
<69 | 92 (46.9%) | 16.92 ± 5.87 | |
≥69 | 104 (53.1%) | 15.59 ± 4.29 | |
PSA (ng/ml) | 0.043 * | ||
<4 | 49 (25%) | 17.63 ± 5.41 | |
≥4 | 116 (59.2%) | 15.89 ± 5.01 | |
Missing data | 31 (15.8%) | – | |
LDHa | 0.585* | ||
<197 | 102 (52.0%) | 16.47 ± 5.42 | |
≥197 | 80 (40.8%) | 16.41 ± 4.60 | |
Missing data | 14 (7.1%) | – | |
SAa | 0.954* | ||
<56 | 110 (56.1%) | 16.38 ± 4.83 | |
≥56 | 71 (36.2%) | 16.62 ± 5.44 | |
Missing data | 15 (7.7%) | – | |
AKPa | 0.364* | ||
<75 | 114 (58.2%) | 16.34 ± 5.58 | |
≥75 | 71 (36.2%) | 16.42 ± 4.11 | |
Missing data | 11 (5.6%) | – | |
Pathological grade group | |||
Low-grade group (<8) | 107 (54.6%) | 16.45 ± 5.31 | 0.531* |
High-grade group (≥8) | 89 (45.4%) | 15.93 ± 4.90 | |
T stage | 0.050 * | ||
T1 and T2 | 141 (71.9%) | 16.73 ± 5.32 | |
T3 and T4 | 55 (28.1%) | 14.89 ± 4.35 | |
N stage | 0.017 * | ||
N0 | 185 (94.4%) | 16.41 ± 5.13 | |
N1 | 11 (5.6%) | 12.91 ± 3.81 | |
Bone metastasis | 0.105a * | ||
No | 99 (50.5%) | 16.74 ± 5.36 | 0.924b * |
Yes | 14 (7.1%) | 14.21 ± 4.14 | |
Suspicion | 23 (11.7%) | 16.30 ± 4.70 | |
Missing data | 60 (30.6%) | – |
Pathological grade falls into high grade and low grade using the GS. Pathological stage is assessed by postoperative pathology results (not biopsy) in accordance with 2002 TNM classification; p < 0.05 is considered as statistically significant.
PCa, prostate cancer; BPH, benign prostate hyperplasia; AFU, alpha-l-fucosidase; PSA, prostate-specific antigen; LDH, lactate dehydrogenase; SA, serum sialic acid; AKP, alkaline phosphatase; GS, Gleason system.
aContinuous variables are expressed as median.
ap: no bone metastases versus bone metastases.
bp: no bone metastases versus suspicion.
*p: Mann–Whitney U-test.
Bold values was used for emphasis, means p ≤ 0.05.